On Nov. 18, 2026, Recursion shares climbed after regulators aligned on its lead familial adenomatous polyposis trial, though ...
This pharmaceutical-development technology company continues to demonstrate that its testing platform has real potential.
Researchers have developed a quasilinear-time subtree prune and regraft algorithm for median quartet tree search that ...
A new sampling algorithm, the open-closed mod-minimizer, reduces the space required for genomic indexes by up to 18 percent ...
WEST LAFAYETTE, Ind. — Quantum computers have the potential to perform calculations more quickly than supercomputers, but they could be even faster and more energy-efficient if they were built with ...
That counts as one round. I repeat this for many rounds, tracking only one number: the longest streak of tails before the ...
In addition to that, given the crosstalk that is known between MAPK pathway and beta-catenin, MEK1/2 can also dampen some of the growth signals driven by APC loss. It is that platform insight that led ...
Good morning, everyone, and thank you for joining Recursion's Third Quarter Earnings Call. We're hosting earnings live from the CGA-IGC Annual Meeting in Denver. Today, we'll share the new FAP data ...
IGC in an expanded adult population aged 18 years and older show deep, durable polyp burden reductions in FAP, with activity throughout the GI tract and in larger, higher-risk polyps.REC-4881 shows ...
New Phase 2 REC-4881 data presented at CGA-IGC in an expanded adult population aged 18 years and older show deep, durable polyp burden ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results